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Purpose: The consistent observation of a reduction of the elastin concentration in 
abdominal aortic aneurysms (AAAs) has led us to investigate in AAA specimens two 
metalloproteinases that display elastase activity, MMP 2 (gelatinase A/72 kDa) and MMI~9 
(gelatinase B/92 kDa). 
Methods: Samples of fitU-thickness aortic wall, adherent hrombus, and serum were 
collected in 10 patients with AAAs. Samples of normal aortic wall and serum were taken 
from 6 age-matched control patients. Quantitative gelatin-zymography and gelatinolytic 
soluble assays after acetyl-phenyl mercuric acid activation were performed on serum and 
tissue extracts, and the results were expressed in units on a comparative wet-weight basis. 
Histologic analysis was performed in parallel to score the inflammatory infiltrate. 
Results: The luminal and parietal parts of the thrombus contained, respectively, 20- and 
10-fold more gelatinolytic activity than the serum. The predominate form was MMP 9. 
Although the total gelatinolytic activity was in the same range both in AAAs and in normal 
walls, a significantly higher proportion ofMMP 9 was found in the aneurysmal ortic walls. 
Furthermore, a significant proportion ofMMP 9 was under its processed active form, which 
was never observed in normal samples. A significantly higher proportion ofMMP 2 was also 
present as processed active form in AAA wall. This latter parameter positively correlated 
with the inflammatory score. 
Conclusions: The presence of activated MMP 9 and MMP 2 might contribute to the 
degradation of the extracellular matrix proteins that occurs during the development of
aneurysms. (J Vasc Surg 1996;24:127-33.) 
Structural alterations of the aortic wall and deg- 
radation of matrix proteins consistently have been 
reported to occur in abdominal aortic aneurysms 
(AAAs) as compared with healthy aorta or with 
atherosclerotic occlusive aorta)3 The analyses that 
we previously performed on tissue fragments col- 
lected from AAAs of  increasing size demonstrated a 
reduction in elastin concentration that occurred ur- 
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ing the early development of the lesion without 
alteration in collagen concentration, whereas an in- 
creased extractability of collagen was observed in the 
ruptured specimens. 4 These alterations might result 
from an increased proteolysis, decreased antipro- 
teolytic activities, or both. 5'6 Increased levels of blood 
and tissue proteinase activities have indeed been 
reported in patients with AAAs; some of  the previous 
studies described a serine-protease 7'8 as the main 
elastolytic activity, whereas other studies howed that 
the elastolytic activity presented features of the family 
of metalloproteinases (MMPs). 9-12 
The MMPs are connective tissue-degrading en- 
zymes that participate in a variety of physiologic 
remodeling processes and in many diseases associated 
with excessive tissue degradation, such as arthritis, 
tumor invasion, periodontitis, and osteoporosis. The 
members of this family share a high level of  gene 
characteristics and common features, such as a Zn- 
dependent catalytic site, requirement of Ca++ for 
activity, and secretion under a latent proenzyme form 
requiring a primary activation by proteolytic en- 
zymes, organomercurials, or chaotropic agents fol- 
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Table I. Material and methods 
Aneurysm diameter Control aorta Control 
66.8+ 10.8 mm <30 mm serum 
Samples 
No. 10 6 6 
Men 8 6 6 
Age (yr) 70.5 + 10.5 77.5 + 10.0 69.0 _+ 6.3 
lowed by an autocatalytic activation by cleavage 
of the propeptide. Their activity in the tissues is 
regulated by specific tissue inhibitors of metallopro- 
teinases (TIMPs)) a MMP 2 (gelatinase A/72 kDa) 
and MMP 9 (gelatinase B/92 kDa) express a broad 
spectrum of activity and have been shown to display 
significant elastase activity, more potent than the 
stromelysins, 14 on purified substrate 15and in organo- 
typic culture of aortic fragments. 16 MMP 2 is pro- 
duced by cells of mesenchymal lineage, whereas 
MMP 9 is secreted by neutrophils, macrophages, and 
macrophage-derived osteoclasts and likewise partici- 
pate in the inflammatory response. The excessive 
degradation of elastin and, perhaps, other non-col- 
lagen matrix components and the presence of an 
inflammatory infiltrate in the wall of AAAs 2,17,18 led us 
to investigate he involvement ofthese MMPs in this 
disease. For this purpose, wc identified and quanti- 
tated MMP 2 and MMP 9 and their extent of activation 
in the wall of AAAs as compared with normal aortic 
walls. As significant amounts of the two enzymes and 
their inhibitors (TIMPs) are present in the circulating 
blood, 19'2° they were evaluated on a comparative unit 
wet-weight basis in the serum and in the wall- 
adherent thrombus at a luminal and parietal location. 
MATERIALS AND METHODS 
Collection of specimens. All tissues and blood 
samples were obtained with the approval of the 
Institutional Ethics Committee of the Liege Univer- 
sity Hospital. Fragments of full-thickness aortic wall 
and adherent thrombus were collected 4 to 5 cm distal 
to the renal arteries in 10 patients undergoing elective 
operative repair. The mean diameter of the AAAs was 
66.8 _ 10.8 mm. A sample of serum was collected 
from each patient. Control aortic samples were col- 
lected at autopsy within 24 hours after death from six 
age-matched patients without known cardiovascular 
disease. Age-matched control serum samples were 
obtained from six volunteers. The mean age was 
70.5 + 10.5 years in the AAA group, 77.5 + 10.0 
years in the control aorta group, and 69 + 6.3 years in 
the control serum group (Table I). A piece of material 
(0.5 to 3 cm 3) was dissected from the luminal and 
parietal side of the thrombus and from the aortic wall, 
quickly frozen, weighed (wet weight), crushed in 
liquid nitrogen, lyophilized, and weighed again (dry 
weight). 
Extraction of MMPs. Aliquots of powdered 
thrombus and aortic wall were extracted (2 ml/100 
mg dry weight) overnight at 4 ° C in 0.05 mol/L Tris 
HC1 pH 7.5, 1 mol/L NaCI, 2 mol/L urea. After 
centrifugation at 15,000 rpm in the cold, the superna- 
tant was collected and used for measurement ofgelati- 
nase activity by a soluble assay and by zymography. 
Soluble assay of gelatinase activity. The gelati- 
nolytic activity present in tissue extracts and serum 
was assayed by using 3H-gelatin as substrate. Type I 
collagen was purified from fetal bovine skin and radio- 
labeled with 3H-acetic anhydride as previously de- 
scribed 21 to a specific activity of 0.79 × 106 cpm/mg 
collagen. Before performing the assay, the all- 
collagen was neutralized with 1 mol/L Tris (base) and 
diluted with 0.05 mol/L Tris-HC1 pH 7.5, 0.2 
mol/L NaC1, 0.5% Triton X-100, 5 mmol/L CaC12, 
3 mmol/L NaN 3 to 5,000 cpm per 50 btl ofsubstrate 
solution, denatured to3H-gelatin by heating 10 min- 
utes at 60 ° C and supplemented with 5 btl of 2.5 
mmol/L solution of protease inhibitors, N-ethyl- 
maleimide (NEM) and phenylmethane sulfonylfluo- 
ride (PMSF). 
Serial dilutions (1/10 to 1/800) of the tissue 
extracts and of the serum, the latter being brought to 
4 mol/L urea before activation, were incubated for 15 
minutes at 25 ° C in the absence or presence of 0.3 
mmol/L acetyl-phenyl mercuric acid (APMA) to 
activate the gelatinases. After APMA activation, some 
samples were supplemented with ethylenediamine 
tetraacetic a id (EDTA) to 10 mmol/L to inactivate 
the MMPs and served as blank values. Nonactivated, 
activated, and EDTA-inhibited samples were incu- 
bated overnight with 5,000 cpm 3H-gelatin at 37 ° C, 
trichloroacetic acid-precipitated (12% final) in the 
cold and centrifuged at 2,000 rpm, and the TCA- 
soluble radioactivity (fragments of gelatin) was mea- 
sured by liquid scintillation spectrometry. The activity 
was calculated from the serial dilutions fitting in the 
linear part of the kinetics curves. The results were 
expressed inunits per mg wet weight (tissue) or per gl 
(serum), one unit being the activity able to degrade 
1 gg of gelatin (=790 cpm) in 16 hours at 37 ° C. 
Zymography assay. Serial dilutions of tissue ex- 
tracts and serum were incubated for 1 hour at room 
temperature in 0.01 mol/L Tris HC1 pH 6.8, 4% so- 
dium dodecylsulfate (SDS) before performing poly- 
acrylamide slab gel electrophoresis according to the 
technique of Laemmli 22 using a separation gel con- 
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Table II. Amount of gelatinolytic measured by soluble assay and by zymography and distribution 
between MMP 2 and MMP 9 
Tissue samples 
Serum Thrombus Wall 
Control AAA Luminal Parietal AAA Control 
(n=6) (n= lO) (n= lOJ (n =10) (n= lO) (n=6) 
Total activity 
Soluble assay* 3.0 -+ 0.9 2.8 _+ 0.8 41.9 + 51.3 13.1 + 15.8 11.1 + 7.8 5.5 + 4.8 
Zymographyt 2.7 + 0.5 5.6 + 2.5~ 125.4 _+ 93.0 68.4 _+ 56.4 71.4 -+ 39.4 53.6 + 44.6 
Distribution (in%) 
MMP 2 55 + 13 56_+ 11 19 + 16 33 + 17 49 + 16 71 _+ 8 
MMP 9 45 + 13 44 + 11 81 + 16 67+ 17 51 + 16~ 29_+ 8 
Results are expressed in units per ~tl of  serum or per mg of wet weight of  tissue, *one unit in soluble assay corresponding to enzyme activity 
degrading 1 btg of  gelatin in 16 hours at 37 ° C and 1-one unit in zymography assay corresponding tobleaching of  1 arbitraryvolume of gelatin 
containing acrylamide gel. 
:~Significantly different from control values, p < 0.02. 
taining 1% gelatin. After migration, the gels were 
washed two times in 2% Triton at 30 ° C and incubated 
at 37 ° C overnight in 0.05 mol/L Tris HC1 pH 7.6, 
10 mmol/L CaC12 to allow for gelatin degradation. 
The gels were stained with Coomassie Blue, the gel- 
atinase bands appearing as white on a blue back- 
ground. The intensity of the bands was recorded with 
a LKB Ultrascan XL laser scanning densitometer. The 
enzyme activities were calculated from the linear part 
of the regression curves relating the intensity of the 
bands and serial dilutions of the tissue extract or 
serum.  
Histologic analysis. The specimens of aortic 
tissue and thrombus, luminal and parietal, were fixed 
in 3.5% saline-buffered formaldehyde and processed 
with standard techniques for paraffin embedding. 
Hematoxylin and eosin-staincd sections were used to 
evaluate the density, localization, and nature of the 
inflammatory cells. The intensity of the inflammatory 
reaction was scored as mild (+), moderate (++), or 
severe (+++). 
Statistical analysis. Statistical analysis was per- 
formed by Student's t test, and the distribution of 
each variable was characterized by the mean and 
standard cviation. Results were considered to be 
significant at the 5% critical evel (p < 0.05). 
RESULTS 
The patterns of distribution ofMMP 2 and MMP 9 
display obvious differences in the various samples 
(Fig. 1). They are representative of the quantitative 
results in Tables II and III. 
Table II illustrates the gelatinolytic activity mea- 
sured by soluble assay and by zymography, expressed 
in units per mg wet weight of extracted tissue or per btl 
(serum), in the serum, extracts of luminal and parietal 
fragments of the thrombus and of the aortic wall from 
the 10 patients with AAAs compared with six normal 
age-matched serum samples and six samples of normal 
aortic wall from age-matched individuals. The distri- 
bution of gelatinolytic activity between MMP 2 and 
MMP 9 is recorded from zymograms and reported as 
the sum of the zymogen and of the processed forms of 
each of the two enzymes. 
All reported activities were inhibited by EDTA, a 
property characteristic of the Ca-dependent MMPs 
and resistant to the thiol-proteinases inhibitor, NEM, 
and to the serine proteinases inhibitor, PMSF. 
Gelatinase activity in the serum. By using the 
soluble assay after APMA activation, the total gelati- 
nase activity measured in the serum was similar in 
AAAs and normal controls whereas two times more 
activity was found in AAA serum by zymography 
(Table II). The gelatinolytic activity was almost 
equally distributed between the MMP 2 and MMP 9 in 
the serum of control and in AAAs. It must be noted 
that in five of the 10 samples of AAAs, around 10% of 
the MMP 9 was found under an activated processed 
form (Table III), whereas none of the control samples 
displayed such processing. 
Gelatinase activity in the thrombus. A high 
level of gelatinolytic activity was observed in the 
luminal thrombus in contact with the blood and, to a 
lesser extent, in the parietal segment of the thrombus 
(Table II). As compared with the activity in the serum 
and expressed on the same basis (1 btl of serum = 1 mg 
wet weight of thrombus), the luminal part of the 
thrombus contained 15 (by soluble assay) to 25 (by 
zymography) times more gelatinolytic activity than 
the serum. These levels dropped in the parietal 
segment of the thrombus. This high gelatinolytic 
activity was mainly a result of MMP9, representing 
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Fig. 1. Representative example of MMP 2 and MMP 9 
activity under latent (92 and 72 kDa) or processed (92 and 
72 kDa act) forms measured by zymography in serum and 
vessel wall (WALL) extracts of normal aorta (N) and AAAs. 
Extracts of samples from luminal (LUM) and parietal 
(PAR) parts of adhering thrombus are also shown. 
80% and 70% of the total activity in the luminal and 
the parietal parts of the thrombus, respectively. In the 
luminal thrombus, no activated form was observed, 
whereas in the parietal thrombus 10% of the MMP 9 
and 30% of the MMP 2 were present as activated 
processed enzyme (Table III). 
Gelatinase activity in the aortic wall. The total 
gelatinase activity measured in the AAA wall was 
similar to that found in the parietal thrombus and did 
not significantly differ from the activity present in the 
normal aortic walls (Table II). Whereas the prepon- 
derant form of gelatinase in the normal aorta was 
MMP2, a significantly higher proportion of MMP 9 
was detected in AAA (p < 0.05). Moreover, asignifi- 
cant proportion of the MMP 9 appeared in the AAA 
wall as fully processed activated enzyme, which was 
never observed in the control aortic wall. The acti- 
vated processed form ofMMP 2 was also significantly 
increased, more than doubled in the wall of AAA as 
compared with controls (Fig. 1 and Table III). A 
gelatinolytic activity migrating above the latent pro- 
MMP 9 was also observed in most of the AAA wall 
samples (Fig. 1). It was not taken into account in the 
calculation of MMP 9 activity. 
Histologic examination. Microscopic examina- 
tion of the AAA wall showed medial and intimal 
fibrosis often associated with atherosclerosis, focal 
calcifications, perivascular sclerosis, and thickening of 
the vasa vasorum. The thrombi consisted of a fibrin- 
ous material infiltrated iffusely or locally by degen- 
erated red cells and rare leukocytes. No obvious 
morphologic difference was found between the lumi- 
nal and the parietal thrombus. Fig. 2 is a representa- 
tive example of our series of specimens, howing the 
low density of the inflammatory infiltrate in the 
luminal (Fig. 2, A) and parietal (Fig. 2, B) side of the 
Table I I I .  Activated forms of MMP 2 and 
MMP 9 gelatinases 
MMP2 MMP9 
Serum control 0 0 
Serum AAA 12 + 12%*t 
Thrombus luminal 0 0 
Thrombus parietal 27 + 24% 9 _+ 10% 
Wall AAA 35 +_ 12%* 21 +_ 15%* 
Wall control 17 + 5% 0 
*Significantly different from control wal s, p < 0.05. 
tResults are expressed in percent of total MMP 2 or MMP 9 activity. 
adherent thrombus and the preferential localization 
of inflammatory cells in the adventitia nd the media 
of the aortic wall (Fig. 2, C). They consisted predomi- 
nantly in mononuclear cells (lymphoplasmacytic cells 
and macrophages) beside some polymorphonuclear 
neutrophils. A linear regression relationship was ten- 
tatively established between the extent of the inflam- 
matory cells infiltrate in the aortic wall and the level of 
expression and activation of the two gelatinases (Table 
IV). The only significant positive correlation (r = 
0.46) was between the level of activated MMP 2 and 
the density of the infiltrate. 
DISCUSSION 
The enzyme activities measured in the serum and 
in the tissue extracts display an array of features pe- 
cific of the MMPs. They are inhibited by EDTA, resis- 
tant to PMSF, and activated by NEM, organomcrcu- 
rials, and SDS. The latent forms and processed forms 
of these enzymes display adequate molecular size as 
compared with the enzyme secreted by A2058 cell 
line for the MMP223 and 12-0-tetradecanoylphorbol- 
13-acetate-induced transformed endothelial cells 
ECV-304 for the MMP924 (data not shown). 
The two assays used for measuring gelatinase 
activity provide somewhat different information. In 
the soluble assay, the activation of the gelatinases i
performed by an organomcrcurial reagent hat does 
not dissociate the enzymes from their complex with 
the TIMPs. This technique therefore measures the 
total free MMP 2 and MMP 9 activities. By zymogra- 
phy, the gelatinases are activated by SDS and dissoci- 
ated from their inhibitors by electrophoresis. This 
technique allows discrimination of the MMP 2 and 
MMP 9 as well as their processed activated forms by 
their molecular size and definition of a distribution 
pattern of each form. This distribution was used to 
calculate the gelatinolytic activity, measured by the 
soluble assay, attributable to each form. The differ- 
ence between the values measured by zymography 
and by the soluble assay provides an indirect estima- 
tion of the TIMPs. 
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Fig. 2. Hematoxylin-eosin tained sections of luminal (A) and parietal (B) side of adherent 
thrombus, which consisted essentially of fibrinous material infiltrated by degenerated red ceils 
and rare leukocytes. The aortic wall (C) shows medial nd intimal fibrosis associated with 
mononuclear cell infiltrate predominating in adventitia nd media. 
Table IV. Relationship between inflammatory ceils infiltrate in aortic wall and latent and activated 
forms of MMP2 and MMP 9 
MMP 9 (units/mg) 
Infiltrate No. Latent Activated 
MMP 2 (units~rag) 
Latent Activated 
+* 2 0.90 (0.78 to 1.17) 0.23 (0.18 to 0.27) 
++ 5 1.47 (0.30 to 2.95) 0.48 (0.03 to 1.47) 
+++ 2 2.86 (0.63 to 5.09) 0.25 (0.25 to 0.26) 
r NS NS 
0.99 (0.24 to 1.75) 
1.05 (0.64 to 2.50) 
1.62 (0.63 to 2.61) 
NS 
0.33 (0.17 to 0.50) 
0.51 (0.22 to 0.99) 
0.83 (0.42 to 1.25) 
0.46 
*Intensity of infiltrate was scored as mild (+), moderate (++), or severe (+++). 
r, Correlation coefficient; NS, not significant. 
The main conclusions that can be drawn from 
our investigations are (1) aneurysmal aortic walls 
contain a significantly higher amount o fMMP 9 than 
control specimens, and (2) the activated processed 
forms of both MMP 2 and MMP 9 are significantly 
increased. 
The two forms ofgelatinolytic a tivity, MMP 2 and 
MMP9, in the serum were almost equally represented, 
both in control patients and in patients with AAAs. 
Latent gelatinases are regular plasma components. 19 
The MMP 9 probably originates from granulocytes. 
This observation is supported by the higher propor- 
tion of the MMP 9 in human serum compared with 
plasma, 2~ as we observed in our samples, probably on 
its release during the in vitro clotting process. The 
MMP 2 originates from multiple cellular sources, as 
discussed by Moutsiakis et al. 2° The higher gelati- 
nolytic activity measured in AAA serum by zymogra- 
phy as compared with the soluble assay suggests that 
circulating elatinase activity might be partly inhib- 
ited by complexing with TIMPs. It is also noteworthy 
that five of the 10 patients with AAAs had a detectable 
amount of the activated processed MMP9, which was 
never detected inthe control group. By examining the 
clinical and biologic parameters in these five patients, 
results indicated that they differed by the size of the 
aneurysmal lesion. The mean aortic diameter of the 
patients who showed no processed MMP 9 form was 
58.0 + 5.7 mm (range, 50 to 65 mm),whereas that in 
the group of patients who showed detectable vels of 
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Fig. 3. Illustration of gradient of decreasing level of 
MMP 9 activity and increasing activation of both MMP 9 and 
MMP 2 from luminal thrombus toward aortic aneurysmal 
wall. *, Significantly different from control values. 
activated MMP 9 was 75.6 + 6.2 mm (range, 65 to 80 
mm). 
The large amount o fMMP 9 activity in the luminal 
part of the thrombus could not be related to its 
sustained release by inflammatory cells because they 
were almost absent in this section of the thrombus. 
The enzyme might have been released uring throm- 
bus formation and sequestered by complex formation 
with other proteins. Both MMP 9 and MMP 2 are 
formed of structural domains that have been shown to 
participate in their binding to matrix components. 26 
In addition to the propeptide, the catalytic, and the 
C-terminal hemopexin-like domain, the MMP 9 con- 
tains a fibronectin4ike r gion and a type V collagen- 
homologous region that might participate in interac- 
tions with extracellular proteins such as fibrin. The 
MMP 2 was found as the predominating form in the 
aortic wall of the control group, whereas asignificant 
shift toward MMP 9 was observed in the AAA speci- 
men. MMP 2 is synthesized by the smooth muscle cells 
of the intima and the media of the wall as well as by the 
adventitial fibroblasts, as described by Herron et al.10 
It does not differ in absolute value in the control and 
AAA groups. The higher proportion o fMMP 9 in the 
AAA is probably related to the presence of inflamma- 
tory cells known to produce this MMP. Itwas recently 
identified by immunohistochemical analysis 17 and in 
situ hybridization 18in macrophages infiltrating the 
aneurysmal aorta. The MMP9-positive cells repre- 
sented, however, a subset of only 10% to 20% of the 
inflammatory cells, is This finding might explain why 
we were unable to find a significant correlation 
between the level of  expression of the MMP 9 in AAA 
and the score of infiltrating cells. Other types of 
inflammatory cells might also produce the MMP9, 
such as neutrophils that present he special feature to 
secrete the monomeric 92 kDa form and a het- 
erodimer of 125 ld3a where the MMP 9 is disulfide- 
linked with a2 microglobulin. 27 The gelatinolytic 
band migrating above the 92 kDa in our AAA wall 
samples might originate from polymorphonuclear 
leukocytes observed in the adventitia nd the media of 
the AAA wall. Recent reports 28'29 identified in AAA, 
besides the MMP9, the stromelysin 1 (MMP3) , inter- 
stitial collagenase (MMP1) in high-molecular weight 
forms and the activated forms o fMMP 9 and MMP 3. 
To our knowledge, our report is the first to demon- 
strate the presence of the activated form o fMMP 2 in 
significantly higher proportion in the AAA than in 
normal aortic wall. The gradient of processing of both 
MMP 2 and MMP 9 observed in our study (Fig. 3) 
increasing from the luminal thrombus toward the 
AAA wall suggests that the activation process might 
originate in the wall. 
Because the aneurysmal aortic wall contains a 
greater amount of MMP 9 with a significant propor- 
tion of activated form, unlike the enzyme in the 
normal aortic wall, and also a significantly larger 
amount of activated MMP2, the possibility exists that 
these enzymes contribute to the degradation of ex- 
tracellular matrix proteins observed in AAA. 
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